AVBCC Value-Based Voices

Rachael
  • 0,0 (0)
  • Phi lợi nhuận

The Association for Value-Based Cancer Care’s (AVBCC) podcast series addresses the ever-evolving landscape of value related to cancer care in the United States. Our goal is to foster informed dialogue, promote transparency, and empower all players to navigate the rapidly changing landscape of cancer care with clarity and confidence.

  1. 5 ngày trước

    Part D Upheaval: Why the Cancer Community Needs to Pay Attention

    In this episode of Value-Based Voices, host Jayson Slotnik, JD, MPH, Partner at Health Policy Strategies, and AVBCC Board Member, sits down with Joel White, Partner and Head of Health Practice at Monument Advocacy, and a principal architect of Medicare Part D, to discuss one of the most consequential challenges facing cancer care today: the end of the Part D Premium Stabilization Demonstration.  Bringing unmatched historical insight, policy fluency, and practical clarity to the conversation, Joel breaks down how we got here, how this decision will affect access to cancer therapies, and the real, actionable solutions that could stabilize the market and protect patients.  Tune in to gain an understanding for this moment and the path forward! Resources & Links:  Medicare Part D overview: https://www.medicare.gov/drug-coverage-part-d Medicare Extra Help / Low-Income Subsidy: https://www.ssa.gov/medicare/part-d-extra-help   Connect with Our Guests:  Connect with Joel White:   / joel-white-6b8a953/ Connect with Jayson Slotnik:   / jayson-slotnik-3932305   Contact Value-Based Voices - Follow AVBCC on LinkedIn   - View our podcast lineup  - Contact us at info@avbcc.org Thanks for listening!

  2. 4 thg 8

    Can the U.S. Keep Its Edge? FDA Policy, China’s Momentum, and the Future of Innovation

    In this follow up conversation, Jayson Slotnik, JD, MPH, Partner at Health Policy Strategies and AVBCC Board Members, and Steve Usdin, Senior Editor, Washington, BioCentury Publications, take a clear eyed look at the future of the FDA and the forces shaping biopharmaceutical innovation. Building on their earlier discussion of FDA history and political dynamics, Steve offers candid insights into how U.S. policy, global competition - particularly with China - and shifting regulatory priorities are influencing the life sciences ecosystem. He explores: - the implications of NIH funding erosion - restrictions on international collaboration - immigration challenges - the growing tension around drug pricing and intellectual property - practical realities companies and investors must navigate in coming months The episode also examines what the FDA can do to strengthen clinical trial efficiency, restore transparency, and rebuild confidence across industry and patient communities. Thoughtful, timely, and grounded in deep policy expertise, this conversation offers listeners a nuanced understanding of where the FDA is headed, and what that means for the future of oncology innovation. If you missed Part 1 of this conversation, catch it here. Resources & Links: BioCentury Publications Operation Trial Blazer Connect with Our Guests: Connect with Steve Usdin  Connect with Jayson Slotnik   Contact Value-Based Voices - Follow AVBCC on LinkedIn   - View our podcast lineup  - Contact us at info@avbcc.org Thanks for listening!

  3. 28 thg 7

    The Future of the FDA: What Comes Next?

    In this first of a 2-part series featuring Steve Usdin, Senior Editor, Washington, BioCentury Publications, host Jayson Slotnik, JD, MPH, Partner at Health Policy Strategies and AVBCC Board Member, leads a spirited conversation around  developments at the FDA, the political influence shaping its decisions, and the outlook for the future.  Key topics covered include: The state of morale among FDA career staff and the challenges in attracting new talentEroding confidence levels within the investor community and implications for fundingPolitical and ideological influence on FDA activities The debate over the upcoming FDA commissioner appointment and potential candidatesThe significance of recent initiatives like Operation Trial Blazer in restoring confidenceOpportunities for optimism with FDA’s recent engagement with rare disease advocates and international collaboration effortsResources & Links:  BioCentury PublicationsOperation Trial BlazerConnect with Our Guests:  Connect with Steve UsdinConnect with Jayson SlotnikContact Value-Based Voices - Follow AVBCC on LinkedIn   - View our podcast lineup  - Contact us at info@avbcc.org Thanks for listening!

  4. 30 thg 6

    Reflections on the NCCN

    In this episode of Value-Based Voices, we delve into the mission and inner workings of the NCCN, a cornerstone organization shaping cancer treatment standards in the U.S. and beyond. We're joined by Bill McGivney, PhD, Principal, McGivney Global Advisors, and Former CEO, NCCN; and host Nicolas Ferreyros, Managing Director, Policy, Advocacy, and Communications, Community Oncology Alliance.  Hear expert insights on how guidelines, payer decisions, and evolving technologies influence patient access and outcomes as well as some of Bill's own thoughts on the NCCN and his time at its helm.  Resources & Links:  National Comprehensive Cancer Network (NCCN)NCCN GuidelinesCommunity Oncology Alliance Connect with Our Guests:  Connect with Bill McGivney Connect with Nicolas Ferreyros Contact Value-Based Voices - Follow AVBCC on LinkedIn   - View our podcast lineup  - Contact us at info@avbcc.org Thanks for listening!

  5. 16 thg 6

    Advancing Cancer Research and Innovation through Collaboration at GCRIS 2026

    We're taking a deep dive into the upcoming Global Cancer Research and Innovation Symposium (GCRIS) in this latest episode of Value-Based Voices. Join GCRIS Scientific Co-chairs Stan Skrzypczak, MS, MBA, Managing Partner, 5 Prime Life Science Consulting, and Nick Sarlis, MD, PhD, FACP, Chief Medical Officer, Cleara Biotech, as they talk with GCRIS Co-chair Matt Vossler, Managing Director, DSG Global, about the groundbreaking science, innovative drug development, and collaborative ecosystems that are reshaping oncology.  Hear about:  - the rise of "biotech 2.0"  - the complexity of bringing new therapies to market - strategies to accelerate drug development cycles and regulatory pathways - what the future holds for researchers and the investors eager to capitalize on emerging science - why GCRIS and its collaborative, unscripted conversations are needed now more than ever Whether you’re in research, investment, or policy, this episode is essential listening for anyone who wants to stay ahead of the curve in cancer innovation.  Request your invitation to attend the GCRIS taking place October 5-6, 2026 in New York City: https://avbcc.org/gcris/ ******************************************** Resources & Links • Swim Across America: https://www.swimacrossamerica.org Contact Value-Based Voices - Follow AVBCC on LinkedIn   - View our podcast lineup  - Contact us at info@avbcc.org Thanks for listening!

  6. 2 thg 6

    Breaking the Model: Can Value-Based Insurance Deliver?

    Most cancer drugs today are more effective and accessible than ever—yet patients often face crushing costs because our healthcare system still values profit over patient benefit. What if the key to transforming cancer care affordability lies in rethinking insurance design, reforming PBMs, and empowering employers with transparent data?  In this eye-opening episode of Value-Based Voices, host Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies, Inc., and Member of the AVBCC Board of Directors, sits down with healthcare thought leader John O'Brien, PharmD, MPH, President and CEO of the National Pharmaceutical Council, and healthcare policy strategist Brian Reid, MS, Senior Fellow at Tufts-CEVR and author of the Cost Curve newsletter. They explore how recent policy shifts, advances in medicine, and innovative data tools could finally create a healthcare environment where high-value cancer treatments reach those who need them most—without unnecessary barriers or skyrocketing costs.  Discover the revolutionary potential of value-based insurance design and how new approaches to drug pricing, formulary placement, and patient cost sharing could reshape the future of cancer care. You'll learn about the critical barriers—such as rebates, rebates-driven formulary decisions, and cost-sharing hurdles—and how a data-rich, employer-led movement could finally tip the balance toward affordability and access. We break down the crucial role of employers, PBMs, and policy reforms in enabling this shift, as well as the clinical, economic, and patient-centered benefits of prioritizing value. With insights from recent research, upcoming innovations in cancer medicine delivery, and a forward-looking view of industry trends, you'll understand why this is the moment to watch for change—and be part of it.  Perfect for healthcare professionals, policymakers, advocates, and anyone impacted by cancer treatment costs—this episode offers a compelling look at the potential to dramatically improve how we deliver and pay for life-saving medicines. If you're ready for a future where affordability meets innovation, this conversation is essential listening.   Resources & Links: - National Pharmaceutical Council - Health Affairs  - Cost Curve Newsletter  - Brian Reid's Website    Connect: - Dr. John O'Brien  - Brian Reid  - Jayson Slotnik  Contact Value-Based Voices - Follow AVBCC on LinkedIn   - View our podcast lineup  - Contact us at info@avbcc.org Thanks for listening!

  7. 19 thg 5

    From the Human Genome Project to 48 Hours: The Rapid Evolution of Tumor Biology

    Most treatments and diagnostics once took years and hundreds of millions of dollars. Today, it costs less than $100,000 to sequence a genome and open the door to tailored cancer therapies that could save lives. But understanding tumor biology is only half the battle. The real challenge lies in interpreting complex genetic data quickly, accurately, and at scale. In this episode of AVBCC’s Value-Based Voices, James Hamrick, MD, MPH, Chair, Precision Oncology Alliance at Caris Life Sciences, teams up with John Fox, MD, MHA, Senior Medical Director for the Americas, Illumina, to explore how AI-driven bioinformatics is making genomic insights accessible and actionable. They reveal concrete strategies to overcome systemic hurdles such as inconsistent testing, reimbursement issues, and integrating insights into busy clinical workflows, that currently hinder widespread, equitable adoption of precision medicine. Discover: How rapid DNA and RNA sequencing is transforming tumor profilingThe critical role of bioinformatics and AI in interpreting complex genomes for real-world useWhy comprehensive multi-omic panels and gene signatures are changing treatments and clinical trialsThe systemic, policy, and reimbursement barriers slowing progress, and what can be done to break them downHow timely, precise testing can reduce costs, improve survival, and personalize treatmentThis isn’t just about technology, it's about unlocking a new era of value-based, patient-centered cancer care that can save lives and resources.  Resources & Links: IlluminaNational Comprehensive Cancer Network (NCCN)Caris Life SciencesConnect with Dr. James Hamrick:LinkedIn Connect with Dr. John Fox:LinkedInContact Value-Based Voices - Follow AVBCC on LinkedIn   - View our podcast lineup  - Contact us at info@avbcc.org Thanks for listening!

  8. 30 thg 4

    Navigating Value and Policy in U.S. Cancer Care and Pharma Pricing

    International reference pricing could drastically reshape drug costs in the U.S. and threaten domestic innovation. In this latest episode of AVBCC’s Value-Based Voices, join Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies, Inc., and Member of the AVBCC Board of Directors, and healthcare policy strategist Brian Reid, MS, Founder of Reid Strategic, as they unpack the complex debate over the proposed international MFN models like Globe, Guard, and Generous — and whether they will do more harm than good for U.S. patients and providers. We break down key insights that every healthcare leader and policymaker must understand including:  ·         The likelihood of lawsuits derailing MFN policies ·         Political winds shifting in favor of international price controls ·         How China’s emerging role could reshape global drug markets  Reid offers a clear framework on the potential legal, economic, and geopolitical impacts of this battle, plus practical predictions about the next steps for PBMs and 340B.  This episode is essential listening for executives, clinicians, and advocates eager to grasp how these international pricing debates could dictate the cost and availability of cancer drugs and other critical medicines in our lifetime Tune in now to navigate the murky waters of international reference pricing and stay ahead of the policy curve that could dramatically alter cancer care in America. Resources & Links: Cost Curve NewsletterBrian Reid's WebsiteConnect with Brian Reid:LinkedIn Connect with Jayson Slotnik:LinkedInContact Value-Based Voices - Follow AVBCC on LinkedIn   - View our podcast lineup  - Contact us at info@avbcc.org Thanks for listening!

Xem tất cả (13)

Giới Thiệu

The Association for Value-Based Cancer Care’s (AVBCC) podcast series addresses the ever-evolving landscape of value related to cancer care in the United States. Our goal is to foster informed dialogue, promote transparency, and empower all players to navigate the rapidly changing landscape of cancer care with clarity and confidence.

Thông Tin

  • Nhà sáng tạo
    Rachael
  • Năm hoạt động
    2026
  • Tập
    13
  • Xếp hạng
    Thô tục
  • Bản quyền
    © 2026 AVBCC Value-Based Voices
  • Trang web chương trình
    AVBCC Value-Based Voices